Timothy Sterling

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. pmc Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis
    Claudia P Cortes
    University of Chile and Fundación Arriarán, Santiago, Chile
    PLoS ONE 8:e74057. 2013
  2. pmc High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility
    Rose Devasia
    University of Louisville School of Medicine, Louisville, Kentucky, USA
    J Clin Microbiol 50:1390-6. 2012
  3. pmc Novel human genetic variants associated with extrapulmonary tuberculosis: a pilot genome wide association study
    Noffisat O Oki
    Bioinformatics Research Center, Department of Statistics, North Carolina State University, Raleigh, NC, USA
    BMC Res Notes 4:28. 2011
  4. pmc Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis
    Alison A Motsinger-Reif
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    BMC Med Genet 11:37. 2010
  5. pmc Black race, sex, and extrapulmonary tuberculosis risk: an observational study
    Christina T Fiske
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
    BMC Infect Dis 10:16. 2010
  6. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
  7. ncbi request reprint Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study
    Timothy R Sterling
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 188:1659-65. 2003
  8. doi request reprint New approaches to the treatment of latent tuberculosis
    Timothy R Sterling
    Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Semin Respir Crit Care Med 29:532-41. 2008
  9. ncbi request reprint Sex-based differences in T lymphocyte responses in HIV-1-seropositive individuals
    Timothy R Sterling
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 191:881-5. 2005
  10. ncbi request reprint The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls
    T R Sterling
    Division of Infectious Diseases, Vanderbilt University Medical Center, 1161 21st Avenue South, A4103 Medical Center North, Nashville, TN 37232 2605, USA
    Int J Tuberc Lung Dis 8:1396-400. 2004

Research Grants

  1. RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS
    Timothy Sterling; Fiscal Year: 2003
  2. Fluoroquinolone Resistance in M. Tuberculosis
    Timothy Sterling; Fiscal Year: 2007
  3. Mentoring in HIV and Tuberculosis Research
    Timothy Sterling; Fiscal Year: 2007
  4. Fluoroquinolone Resistance in M. Tuberculosis
    Timothy Sterling; Fiscal Year: 2009
  5. Fluoroquinolone Resistance in M. Tuberculosis
    Timothy R Sterling; Fiscal Year: 2010

Detail Information

Publications70

  1. pmc Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis
    Claudia P Cortes
    University of Chile and Fundación Arriarán, Santiago, Chile
    PLoS ONE 8:e74057. 2013
    ....
  2. pmc High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility
    Rose Devasia
    University of Louisville School of Medicine, Louisville, Kentucky, USA
    J Clin Microbiol 50:1390-6. 2012
    ..016). In summary, almost half of fluoroquinolone-resistant M. tuberculosis isolates did not have previously described resistance mutations, which has implications for genotypic diagnostic tests...
  3. pmc Novel human genetic variants associated with extrapulmonary tuberculosis: a pilot genome wide association study
    Noffisat O Oki
    Bioinformatics Research Center, Department of Statistics, North Carolina State University, Raleigh, NC, USA
    BMC Res Notes 4:28. 2011
    ..abstract:..
  4. pmc Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis
    Alison A Motsinger-Reif
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    BMC Med Genet 11:37. 2010
    ..Human genetic variants may affect tuberculosis susceptibility, but the immunologic correlates of the genetic variants identified are often unclear...
  5. pmc Black race, sex, and extrapulmonary tuberculosis risk: an observational study
    Christina T Fiske
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
    BMC Infect Dis 10:16. 2010
    ..Our objective was to determine race and sex differences in extrapulmonary tuberculosis risk in order to identify the optimal population in which to assess for host factors associated with extrapulmonary tuberculosis...
  6. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
    ..10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed...
  7. ncbi request reprint Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study
    Timothy R Sterling
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 188:1659-65. 2003
    ..HAART should be initiated at CD4+ lymphocyte counts of >200 cells/mm3...
  8. doi request reprint New approaches to the treatment of latent tuberculosis
    Timothy R Sterling
    Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Semin Respir Crit Care Med 29:532-41. 2008
    ..g., isoniazid + rifapentine for 3 months). Potential future regimens and experimental approaches are also discussed...
  9. ncbi request reprint Sex-based differences in T lymphocyte responses in HIV-1-seropositive individuals
    Timothy R Sterling
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 191:881-5. 2005
    ....
  10. ncbi request reprint The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls
    T R Sterling
    Division of Infectious Diseases, Vanderbilt University Medical Center, 1161 21st Avenue South, A4103 Medical Center North, Nashville, TN 37232 2605, USA
    Int J Tuberc Lung Dis 8:1396-400. 2004
    ....
  11. doi request reprint HIV infection-related tuberculosis: clinical manifestations and treatment
    Timothy R Sterling
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Clin Infect Dis 50:S223-30. 2010
    ..There are also differences in treatment of HIV infection-related TB because of overlapping drug toxicities and drug-drug interactions between antiretroviral therapy and anti-TB therapy...
  12. ncbi request reprint The scope and impact of treatment of latent tuberculosis infection in the United States and Canada
    Timothy R Sterling
    Division of Infectious Diseases and Center for Health Services Research, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
    Am J Respir Crit Care Med 173:927-31. 2006
    ..Identifying the types of clinics that administer such treatment and patients who receive it could guide resource utilization and improve treatment initiation and completion...
  13. ncbi request reprint Immune function in young children with previous pulmonary or miliary/meningeal tuberculosis and impact of BCG vaccination
    Timothy R Sterling
    Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN 37232 2605, USA
    Pediatrics 120:e912-21. 2007
    ..BCG vaccine protects against miliary/meningeal tuberculosis, but the mechanism of protection is unknown. We assessed for abnormalities in immune response associated with miliary/meningeal or pulmonary tuberculosis in young children...
  14. ncbi request reprint Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors
    T R Sterling
    Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Int J Tuberc Lung Dis 10:542-9. 2006
    ..North America...
  15. pmc Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening
    Timothy R Sterling
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    J Infect Dis 204:893-901. 2011
    ..Identifying factors associated with developing tuberculosis after HAART initiation could focus screening efforts...
  16. doi request reprint Three months of rifapentine and isoniazid for latent tuberculosis infection
    Timothy R Sterling
    Vanderbilt University School of Medicine, Nashville, TN, USA
    N Engl J Med 365:2155-66. 2011
    ..The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion...
  17. ncbi request reprint Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy
    Jennifer H Tai
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    J Infect Dis 196:1044-52. 2007
    ..Before the availability of highly active antiretroviral therapy (HAART), there was no clear effect of pregnancy on human immunodeficiency virus (HIV) disease progression. This has not been assessed during the HAART era...
  18. ncbi request reprint Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease
    Timothy R Sterling
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, 424 N Bond Street, Rm 117, Baltimore, MD 21231, USA
    J Infect Dis 186:1181-5. 2002
    ..Heat-denatured p24 antigen level predicted subsequent clinical disease progression in early-stage HIV-1 infection and correlated with both CD4(+) lymphocyte count and HIV-1 RNA level...
  19. pmc Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure
    Rose A Devasia
    Division of Infectious Diseases, Center for Education and Research on Therapeutics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2582, USA
    Am J Respir Crit Care Med 180:365-70. 2009
    ..They have the potential to become first-line antituberculosis therapy, but the effect of fluoroquinolone use on fluoroquinolone resistance in Mycobacterium tuberculosis is not well characterized...
  20. doi request reprint Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care
    Diana C Lemly
    School of Medicine, Department of Biostatistics, Vanderbilt University, Nashville, TN 37203, USA
    J Infect Dis 199:991-8. 2009
    ..There are conflicting data regarding race, sex, and mortality among persons infected with human immunodeficiency virus (HIV). We studied all-cause mortality among persons in care during the highly-active antiretroviral therapy (HAART) era...
  21. ncbi request reprint Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy
    Cunlin Wang
    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
    J Infect Dis 190:1046-54. 2004
    ..The optimal time to initiate highly active antiretroviral therapy (HAART) remains unclear...
  22. ncbi request reprint Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis
    Joshua T Schiffer
    Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, USA
    J Acquir Immune Defic Syndr 44:229-34. 2007
    ..6%. These results support early initiation of HAART in patients with AIDS, except when IRIS-related mortality rates are high...
  23. ncbi request reprint Fluoroquinolone resistance in patients with newly diagnosed tuberculosis
    Amy Sarah Ginsburg
    Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Infect Dis 37:1448-52. 2003
    ..The incidence of M. tuberculosis fluoroquinolone resistance in this small sample of patients with newly diagnosed tuberculosis was high, particularly among patients with prior fluoroquinolone exposure...
  24. doi request reprint Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy
    Yukari C Manabe
    Center for Tuberculosis Research, Department of Medicine, School of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA
    J Infect Dis 199:437-44. 2009
    ..TB diagnostics with improved sensitivity and specificity are urgently needed to detect subclinical TB before it is unmasked...
  25. ncbi request reprint Serum albumin as a prognostic indicator for HIV disease progression
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland 21205, USA
    AIDS Res Hum Retroviruses 22:14-21. 2006
    ....
  26. pmc Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america
    Alison G Abraham
    Bloomberg School of Public Health, Johns Hopkins University, 615 North Wolfe Street, Suite E7640, Baltimore, MD 21205, USA
    Am J Epidemiol 174:727-35. 2011
    ....
  27. ncbi request reprint Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy
    Todd Hulgan
    Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Infect Dis 195:425-31. 2007
    ....
  28. pmc Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance
    Rose A Devasia
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 2582, USA
    J Antimicrob Chemother 63:1173-8. 2009
    ....
  29. ncbi request reprint Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity
    Marylyn D Ritchie
    Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Infect Dis 43:779-82. 2006
    ..Decreased risk of hepatotoxicity was associated with MDR1 3435C-->T (odds ratio, 0.254; P=.021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P<.001)...
  30. ncbi request reprint Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease
    Pinky D Gaba
    Department of Medicine, Division of Infectious Diseases, Vanderbilt University, 1161 21st Ave, A2209 MCN, Nashville, TN 37232 2582, USA
    Arch Intern Med 167:2317-22. 2007
    ..Rates of fluoroquinolone exposure before tuberculosis diagnosis and the impact of fluoroquinolones on culture-negative tuberculosis have not been previously reported...
  31. pmc Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy
    Bryan E Shepherd
    Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Epidemiology 21:698-705. 2010
    ..We sought to expand this understanding using a novel statistical approach proposed by Robins et al...
  32. pmc Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response
    Vlada V Melekhin
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
    PLoS ONE 4:e6961. 2009
    ..The effect of timing of HAART initiation relative to pregnancy on maternal virologic, immunologic and clinical outcomes has not been assessed...
  33. pmc Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators
    Bryan E Shepherd
    Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN 37232 2158, USA
    J Clin Epidemiol 62:729-37. 2009
    ..To evaluate a model for predicting time to AIDS or death among HIV-infected persons initiating highly active antiretroviral therapy (HAART)...
  34. pmc Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors
    Shaheena Asad
    Department of Internal Medicine, Divisions of Hematology Oncology, University School of Medicine, Nashville, TN, USA
    J Natl Med Assoc 100:1417-24. 2008
    ..We performed an observational cohort study to determine the influence of race, sex and other sociodemographic factors on early ART discontinuations among HIV-infected persons...
  35. doi request reprint Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis
    Susan E Dorman
    Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland 21231, USA
    Am J Respir Crit Care Med 180:273-80. 2009
    ..Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in humans are limited...
  36. pmc Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States
    Vlada V Melekhin
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    AIDS Patient Care STDS 24:279-86. 2010
    ..Larger studies with longer follow-up are indicated to assess this association...
  37. ncbi request reprint Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use
    Richard E Nettles
    Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Clin Infect Dis 38:731-6. 2004
    ..ARR tuberculosis can occur with rifampin-based regimens, but in this study, the risk was not significantly higher than that for a rifabutin-based regimen...
  38. ncbi request reprint Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons
    Todd Hulgan
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Acquir Immune Defic Syndr 38:277-82. 2005
    ..0% of combinations to 20.8% during the same periods (P < 0.001). Use of PIs and statins has increased in the adult TennCare population. Contraindicated combinations have decreased but remain unacceptably high...
  39. ncbi request reprint CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3
    Todd Hulgan
    Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    J Infect Dis 192:950-7. 2005
    ..CD4 lymphocyte percentage could add prognostic information...
  40. ncbi request reprint Prognostic factors for survival differ according to CD4+ cell count among HIV-infected injection drug users: pre-HAART and HAART eras
    Noya Galai
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 38:74-81. 2005
    ..Clinical and behavioral variables provided prognostic information about survival, including substance use indicators...
  41. ncbi request reprint Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy
    Marc Weiner
    Department of Medicine, South Texas Veterans Health Care System, San Antonio, Texas 78229, USA
    Am J Respir Crit Care Med 169:1191-7. 2004
    ..The present pharmacokinetic study supports further trials to determine the optimal rifapentine dose for treatment of tuberculosis...
  42. ncbi request reprint Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity
    Timothy R Sterling
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Clin Infect Dis 36:812-5. 2003
    ..These findings support the recommendation that HAART not be initiated for patients with CD4(+) cell counts of >350 cells/mm(3)...
  43. pmc Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures
    Peter F Rebeiro
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2582, USA
    Clin Infect Dis 47:1354-7. 2008
    ..This artifact is attributable to shipping frozen plasma in primary plasma preparation tubes and is not caused by the HIV-1 RNA detection assay; it can be avoided by shipping plasma in a secondary tube...
  44. ncbi request reprint Decreased CD4+ lymphocytes and innate immune responses in adults with previous extrapulmonary tuberculosis
    Paulo R Z Antas
    Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2605, USA
    J Allergy Clin Immunol 117:916-23. 2006
    ..Extrapulmonary tuberculosis is presumably a marker of immunodeficiency, but cytokine responses have not been well studied in such patients...
  45. ncbi request reprint Transmission of Mycobacterium tuberculosis from health care workers
    Timothy R Sterling
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, USA
    N Engl J Med 355:118-21. 2006
  46. ncbi request reprint HIV in the workplace in Botswana: incidence, prevalence, and disease severity
    Elisabeth D Riviello
    Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    AIDS Res Hum Retroviruses 23:1453-60. 2007
    ..These results highlight the need for routine HIV testing and access to antiretro-viral treatment for workers in countries such as Botswana...
  47. ncbi request reprint Treatment of latent tuberculosis infection: challenges and prospects
    Kelly E Dooley
    Department of Medicine, Providence Portland Medical Center, 4805 NE Glissan Street, Portland, OR 97213, USA
    Clin Chest Med 26:313-26, vii. 2005
    ..This article reviews the treatment of latent tuberculosis infection in HIV-seropositive and HIV-seronegative persons...
  48. ncbi request reprint Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis
    Kelly E Dooley
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Clin Infect Dis 34:1607-12. 2002
    ..04). Initial empiric therapy with a fluoroquinolone was associated with a delay in the initiation of appropriate antituberculosis treatment...
  49. pmc Late presentation for human immunodeficiency virus care in the United States and Canada
    Keri N Althoff
    Johns Hopkins University, Baltimore, Maryland, USA
    Clin Infect Dis 50:1512-20. 2010
    ..CONCLUSION. CD4 count at first presentation for HIV care has increased annually over the past 11 years but has remained <350 cells/mm(3), which suggests the urgent need for earlier HIV diagnosis and treatment...
  50. pmc Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)
    Stephen J Gange
    NA ACCORD Coordinating Center, Baltimore, MD 21287, USA
    Int J Epidemiol 36:294-301. 2007
  51. pmc Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis
    Timothy R Sterling
    Johns Hopkins University Center for Tuberculosis Research, 424 N Bond Street, Baltimore, MD 21231, USA
    BMJ 326:574. 2003
    ..This study sought to determine the impact of the World Health Organization's directly observed treatment strategy (DOTS) compared with that of DOTS-plus on tuberculosis deaths, mainly in the developing world...
  52. ncbi request reprint Reversible posterior leukoencephalopathy in an HIV-infected patient with thrombotic thrombocytopenic purpura
    Shelley L Sylvester
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Scand J Infect Dis 34:706-9. 2002
    ..We discuss reversible posterior leukoencephalopathy as a diagnostic clue in HIV-infected patients with multi-organ system disease...
  53. ncbi request reprint When to start HAART, and what to start
    Timothy R Sterling
    Hopkins HIV Rep 15:5. 2003
  54. ncbi request reprint Treatment of tuberculosis in the HIV-infected patient
    Timothy R Sterling
    Hopkins HIV Rep 15:3. 2003
  55. ncbi request reprint Antiretroviral therapy: when to start & what to start with
    Timothy R Sterling
    Hopkins HIV Rep 14:1-4, 16. 2002
  56. ncbi request reprint A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment
    Naomi N Bock
    Division of TB Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia 30030, USA
    Am J Respir Crit Care Med 165:1526-30. 2002
    ..Further evaluation of the safety and tolerability of rifapentine 1,200 mg is warranted...
  57. ncbi request reprint Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients
    Lynn Morris
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Sandringham, Johannesburg, South Africa
    J Infect Dis 187:1967-71. 2003
    ..CD4 counts and virus loads did not change during therapy. Expression of CD38 and HLA-DR remained high throughout treatment, whereas plasma levels of interleukin-6 decreased over time...
  58. ncbi request reprint Tuberculosis
    Thomas R Frieden
    New York City Department of Health and Mental Hygiene, New York, NY 10013, USA
    Lancet 362:887-99. 2003
    ..Until tuberculosis is controlled worldwide, it will continue to be a major killer in less-developed countries and a constant threat in most of the more-developed countries...
  59. ncbi request reprint The rapid development of fluoroquinolone resistance in M. tuberculosis
    Amy Sarah Ginsburg
    N Engl J Med 349:1977-8. 2003
  60. ncbi request reprint Lack of weight gain and relapse risk in a large tuberculosis treatment trial
    Awal Khan
    TBTC Data and Coordinating Center, Clinical and Health System Research Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Am J Respir Crit Care Med 174:344-8. 2006
    ..Readily identified markers of tuberculosis relapse risk are needed, particularly in resource-limited settings. The association between weight gain or loss during antituberculosis therapy and relapse has not been well studied...
  61. ncbi request reprint Drug-resistant tuberculosis in New York City: lessons to remember
    Timothy R Sterling
    Clin Infect Dis 42:1711-2. 2006
  62. ncbi request reprint When to start HAART: still a controversy. Report from Seattle: the 9th Conference on Retroviruses and Opportunistic Infections (CROI)
    Timothy R Sterling
    Hopkins HIV Rep 14:1-3. 2002
  63. ncbi request reprint Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection
    David Vlahov
    Center for Urban Epidemiologic Studies, New York Academy of Medicine, New York, NY 10029, USA
    Am J Epidemiol 161:999-1012. 2005
    ..37/microl, respectively), suggesting that changing indications for treatment may have contributed to improved survival and that analyses restricted to the HAART era probably underestimate HAART effectiveness...
  64. ncbi request reprint An official ATS statement: hepatotoxicity of antituberculosis therapy
    Jussi J Saukkonen
    Am J Respir Crit Care Med 174:935-52. 2006
    ..Priorities for future studies to develop safer treatments for LTBI and for TB disease are presented...
  65. ncbi request reprint Tuberculosis and HIV
    Karen A Wendel
    AIDS Clin Care 14:9-15. 2002
  66. doi request reprint Misdiagnosis of HIV infection: implications for universal testing
    Dawn E Maddux
    AIDS 22:546-7. 2008
  67. ncbi request reprint Pharmacokinetics of rifapentine in children
    Michael J Blake
    Department of Pediatrics, University of Missouri Kansas City, School of Medicine, USA
    Pediatr Infect Dis J 25:405-9. 2006
    ..Although the pharmacokinetics of rifapentine has been investigated in adolescents and adults, no studies have assessed the pharmacokinetics of this drug in children or infants...
  68. ncbi request reprint Stability of antituberculosis drugs mixed in food
    Charles A Peloquin
    Clin Infect Dis 45:521. 2007
  69. ncbi request reprint Extensively drug-resistant tuberculosis: are we learning from history or repeating it?
    Carol Dukes Hamilton
    Duke University School of Medicine, Durham, NC 27710, USA
    Clin Infect Dis 45:338-42. 2007
    ..We urge the development of shorter, less toxic TB treatment and prevention regimens. Funding of TB control and research should be reassessed to prevent budget cuts at a time when the disease is killing as many as 2 million people a year...
  70. ncbi request reprint Use of DNA fingerprinting to investigate a multiyear, multistate tuberculosis outbreak
    Peter D McElroy
    Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Emerg Infect Dis 8:1252-6. 2002
    ..The outbreak demonstrates the need for strategies to detect links among patients diagnosed with TB across multiple TB control jurisdictions...

Research Grants8

  1. RISK FACTORS FOR EXTRAPULMONARY TUBERCULOSIS
    Timothy Sterling; Fiscal Year: 2003
    ..The insights gained may also lead to an improved understanding of the mechanisms through which BCG protects against TB, and identify ways in which to develop a more effective TB vaccine. ..
  2. Fluoroquinolone Resistance in M. Tuberculosis
    Timothy Sterling; Fiscal Year: 2007
    ..tuberculosis would clarify whether fluoroquinolones are indeed a viable option for the first-line treatment of tuberculosis, and how best to preserve their usefulness against tuberculosis. ..
  3. Mentoring in HIV and Tuberculosis Research
    Timothy Sterling; Fiscal Year: 2007
    ..The K24 award will allow Dr. Sterling to continue to pursue his highly-productive career in patient-oriented research in HIV and tuberculosis, and mentor the next generation of researchers to do the same. ..
  4. Fluoroquinolone Resistance in M. Tuberculosis
    Timothy Sterling; Fiscal Year: 2009
    ..tuberculosis would clarify whether fluoroquinolones are indeed a viable option for the first-line treatment of tuberculosis, and how best to preserve their usefulness against tuberculosis. ..
  5. Fluoroquinolone Resistance in M. Tuberculosis
    Timothy R Sterling; Fiscal Year: 2010
    ..tuberculosis would clarify whether fluoroquinolones are indeed a viable option for the first-line treatment of tuberculosis, and how best to preserve their usefulness against tuberculosis. ..